Key facts
- It has raised $440K; the latest was Early Stage VC ($410K) in Feb 2026.
- Notable investors include Leiden University, LifeSciences@Work, UNIIQ.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Omivera
- ·The full record, as it builds
Funding rounds
No funding rounds for Omivera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Omivera
Provider of advanced drug-screening services intended to provide drug discovery and actionable insights. The company's platform provides services such as drug selective profiling, target deconvolution and chemical proteomics to measure how drugs interact with proteins within living cells, enabling companies to meet their drug discovery requirements.
- Sector
- Healthcare
- HQ
- Leiden, Netherlands
- Website
- omivera.com/
- Ownership
- Privately Held (backing)
Omivera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omivera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omivera in its N-PORT filings yet. We sweep new filings monthly.